Search

US-12617971-B2 - Anti-viral coating composition, and method for fixing anti-viral fusion protein to surfaces

US12617971B2US 12617971 B2US12617971 B2US 12617971B2US-12617971-B2

Abstract

An antiviral coating composition is provided. An antiviral coating composition according to one embodiment of the present invention is implemented by including an antiviral component comprising an antiviral fusion protein in which an antiviral motif is bound to an adhesive protein. According to the present invention, the composition has excellent processability enabling easy provision on various surfaces of various products, has adhesion sustainability enabling an adhesive state to be maintained for a long period of time after being adhered to a surface, and has activity sustainability enabling antiviral activity to be maintained for a long period of time without a loss in activity according to external conditions during preparation, storage and use.

Inventors

  • In Yong Seo
  • Dong Sik SEO
  • Seon Ho Jang

Assignees

  • AMOLIFESCIENCE CO., LTD.

Dates

Publication Date
20260505
Application Date
20210520
Priority Date
20200520

Claims (10)

  1. 1 . A method for immobilizing an antiviral fusion protein on a surface, the method comprising: preparing a first solution comprising an antiviral component and water, and a second solution comprising an aggregation-inducing component and ethanol, wherein the antiviral component comprises the antiviral fusion protein in which an antiviral motif is bound to the C-terminus or N-terminus of an adhesive protein, and wherein the aggregation-inducing component comprises a carbodiimide-based coupling agent and a hydroxy succinimide-based reactive agent; mixing the first solution and the second solution in an electrospraying device to prepare an antiviral coating composition; treating the surface with the antiviral coating composition through electrospraying; and drying the antiviral coating composition on the surface.
  2. 2 . The method of claim 1 , wherein a temperature of the second solution is 0 to 15° C.
  3. 3 . The method of claim 1 , further comprising: modifying a tyrosine residue possessed by the adhesive protein in the antiviral fusion protein into a DOPA residue before the treating of the surface with the antiviral coating composition.
  4. 4 . The method of claim 3 , wherein the modification comprises: (1) preparing a solution in which the antiviral fusion protein is dissolved in a buffer solution containing ascorbic acid at a concentration of 25 to 100 mM such that the concentration is 0.1 to 10 mg/ml; (2) preparing the solution in an oxygen-saturated state, and then modifying the tyrosine residue in the adhesive protein into the DOPA residue by mixing tyrosinase with the solution; and (3) performing desalting with acetic acid.
  5. 5 . The method of claim 1 , wherein the antiviral motif is a peptide selected from the group consisting of amino acid sequences of SEQ ID NOS: 1 to 8 or a peptide in which one or more of the amino acid sequences are linked.
  6. 6 . The method of claim 1 , wherein the adhesive protein is selected from the group consisting of amino acid sequences of SEQ ID NOS: 9 to 22 or a protein in which one or more of the amino acid sequences are linked.
  7. 7 . The method of claim 1 , wherein the adhesive protein is a mussel-derived adhesive protein.
  8. 8 . The method of claim 1 , wherein the antiviral coating composition further comprises sodium acetate as an active component that activates the aggregation-inducing component.
  9. 9 . The method of claim 1 , wherein the carbodiimide-based coupling agent and the hydroxy succinimide-based reactive agent are comprised in the aggregation-inducing component at a weight ratio of 1:0.5 to 20.
  10. 10 . The method of claim 1 , comprising mixing the carbodiimide-based coupling agent in an amount of 50 to 200 parts by weight with respect to 100 parts by weight of the antiviral fusion protein.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a 35 U.S.C. 371 National Phase Entry Application from PCT/KR2021/006294 filed May 20, 2021, which claims priority to and the benefit of Korean Patent Application Nos. 10-2020-0060232, 10-2020-0060233 and 10-2020-0060234, all filed on May 20, 2020, the disclosures of which are incorporated herein by reference in their entirety. The instant application contains a Sequence Listing which has been submitted via EFS-Web and is hereby incorporated by reference in its entirety. Said Sequence Listing, created on Nov. 18, 2022, is named SOP116078US.ST25.TXT and is 13000 bytes in size. TECHNICAL FIELD The present invention relates to a coating composition, and more particularly, to a coating composition having antiviral activity and a method for immobilizing an antiviral fusion protein on surfaces. BACKGROUND SARS, which began to spread in early 2003, MERS, which began infecting people in 2012 and also caused 186 cases in South Korea in 2015, and COVID-19 that began in late 2019 and has spread all over the world to date are all caused by viruses, and the need for a sanitary and safe living environment has significantly increased against this background. In particular, considering that it takes a considerable amount of time to develop a vaccine after the outbreak of diseases caused by viruses, the demand for various antiviral products to create a safe living environment is further increasing. All of the above-described diseases are caused by coronaviruses, and ethanol, sodium hypochlorite, an iodophor, peracetic acid, formaldehyde, glutaraldehyde, and ethylene oxide gas are reported to be effective as disinfectants against coronaviruses. Further, 1-adamantanamine hydrochloride, thiosemicarbazide, an arabinosyl nucleoside, nucleoside, 2,3-dideoxynucleoside, pyrophosphate derivatives and the like are known as antiviral agents. However, since the activity of these antiviral components is temporary or the activity may be easily lost due to various external factors such as temperature and humidity, the antiviral effect and durability of antiviral products cannot be expected. In addition, even when there is an antiviral effect by itself, antiviral activity is lost during the process of applying the components to products or there is also a problem in that a process of providing products with antiviral components is not easy. Furthermore, even when a product is provided with an antiviral component while maintaining antiviral activity, there are a durability problem such as easy detachment from the product and a storage stability problem such as loss of activity during storage at room temperature. SUMMARY OF THE INVENTION The present invention has been devised in consideration of the above points, and an object of the present invention is to provide an antiviral coating composition having excellent processability enabling easy provision on various surfaces of various products, having adhesion sustainability enabling an adhesive state to be maintained for a long period of time after being adhered to a surface, and having activity sustainability enabling antiviral activity to be maintained for a long period of time without a loss in activity according to external conditions during preparation, storage and use, and a method for immobilizing an antiviral fusion protein on surfaces. To solve the above-described problems, the present invention provides an antiviral coating composition including an antiviral component including an antiviral fusion protein in which an antiviral motif is bound to an adhesive protein. According to one embodiment of the present invention, the antiviral motif may be bound to the C-terminus or N-terminus of the adhesive protein. Further, the antiviral motif may target a protein that binds to a host cell receptor to disable or disrupt the protein, or may perform the function of disrupting the viral membrane. In addition, the antiviral motif may include any one peptide selected from the group consisting of amino acid sequences of SEQ ID NOS: 1 to 8 or a peptide in which one or more amino acid sequences selected from the above group are linked, or may consist of them. Furthermore, the adhesive protein may be a mussel-derived adhesive protein. Further, the adhesive protein may include any one protein selected from the group consisting of amino acid sequences of SEQ ID NOS: 9 to 22 or a protein in which one or more amino acid sequences selected from the above group are linked, or may consist of them. In addition, the adhesive protein may contain a DOPA residue. In this case, the DOPA residue may be a DOPA residue into which some or all tyrosine residues of the adhesive protein are modified through an enzyme. Furthermore, an aggregation-inducing component including a carbodiimide-based coupling agent and a hydroxy succinimide-based reactive agent may be further included. Further, an active component activating the aggregation-inducing component may be f